Hermes
Closed Pre-Solicitation Posted
- Solicitation number
- HR001124S0025
- Agency
-
Defense Advanced Research Projects Agency
Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Advanced Research Projects Agency (DARPA) is seeking innovative proposals to develop systemic drug delivery platforms for medical countermeasures through the Hermes program. The proposals must include detailed information on the delivery platform, including screening pipelines, reporter systems for monitoring biodistribution and expression in animal models, methods to monitor immunogenicity and toxicity, and the chosen therapeutic cargo. DARPA is looking for transformative approaches that enable exceptional systemic biodistribution, endosomal escape efficiency, and minimal toxicity. Proposals are due by June 11, 2024, and DARPA will hold an industry day on April 8, 2024 to provide additional details.
This opportunity has no set-aside designation. DARPA anticipates awarding multiple procurement contracts, cooperative agreements, or other transactions through this Broad Agency Announcement. The estimated total cost and period of performance should be provided in the abstract, which is due by May 3, 2024. Successful proposals will have their delivery platforms transferred to U.S. Government stakeholders for further development.
Notice text
The Defense Advanced Research Projects Agency (DARPA) is soliciting innovative proposals to develop systemic drug delivery platforms for medical countermeasures (MCMs). The Hermes program is explicitly seeking transformative approaches enabling the development of delivery platforms with systemic biodistribution, exceptional endosomal escape efficiency, and minimal toxicity. Successful proposals will include a detailed description of the proposed delivery platform including 1) screening pipeline, 2) reporter systems for monitoring biodistribution and expression in animal models, 3) methods to monitor immunogenicity/toxicity, and 4) chosen therapeutic cargo and justification. Systemic delivery platforms developed under the Hermes effort will be transferred to U.S. Government stakeholders for further development.
Files
| File | Type | Posted |
|---|---|---|
| HR001124S0025-Amendment-01.pdf | ||
| HERMES_BAA_Attachment_C_Proposal_Summary_Slide_Template.pptx | PPTX presentation | |
| HERMES_BAA_Attachment_D_Proposal_Instructions_and_Volume_I_Template__Technical_and_Management.docx | DOCX document | |
| HERMES_BAA_Attachment_A_Abstract_Summary_Side_Template.pptx | PPTX presentation | |
| HR001124S0025.pdf | ||
| HERMES_BAA_Attachment_F_DARPAStandardCostProposalSpreadsheetSingleTA.xlsx | XLSX spreadsheet | |
| HERMES_BAA_Attachment_E_Proposal_Instructions_and_Volume_II_Template__Cost.docx | DOCX document | |
| HERMES_BAA_Attachment_B_Abstract_Instructions_and_Template.docx | DOCX document |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity